Every 424B that Peraso, Inc. (PRSO) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow PRSO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PRSO filings page.
Peraso Inc. is registering the resale of up to 31,750,000 shares of common stock by Roth Principal Investments, LLC under a committed equity facility. Peraso may, at its sole discretion over up to 36 months, sell shares to Roth for up to $25,000,000, priced off VWAP with discounts of 3.0% for Market Open and Intraday purchases and 5.0% for Pre- and Post-Market purchases. Peraso receives proceeds only from its sales to Roth, not from Roth’s resales.
Nasdaq rules cap issuances to Roth at 3,004,114 shares (19.99%) unless shareholders approve more or the average purchase price is at least $0.9853, and Roth cannot exceed a 4.99% Beneficial Ownership Limitation. Peraso had 15,040,679 shares outstanding as of June 23, 2026; if all 31,750,000 shares were issued, they would represent 67.9% of outstanding shares and non-affiliate holdings as of that date. A $500,000 commitment fee and legal reimbursements are payable to Roth, and Peraso expects to use any net proceeds for working capital and general corporate purposes, including product development and expansion in drone, defense and tactical communications markets.
PRSO supplements its Form S-3 prospectus to increase the amount available under an At-the-Market sales agreement with Ladenburg Thalmann to permit up to $670,000 aggregate offering price of common stock to be sold from time to time. The supplement states prior sales under the program totaled approximately $9,370,130. The company reports a public float of $27,523,842 based on 14,718,632 shares outstanding as of May 12, 2026 and a last reported Nasdaq sale price of $0.9793 on May 13, 2026. Sales under General Instruction I.B.6 of Form S-3 remain subject to the one-third-of-public-float limit in any 12-month period; PRSO reports it sold $8,502,675 in the prior 12 months under that instruction.
PRSO amends its shelf prospectus to increase at-the-market capacity to an aggregate offering price of up to $2,125,000. The supplement updates the Sales Agreement with Ladenburg Thalmann & Co. Inc. and notes approximately $7,245,131 in aggregate sales made under prior prospectus supplements.
As of April 10, 2026, the filing reports a public float of $25,732,336 based on 12,613,890 shares outstanding and a closing price of $2.04 per share (March 6, 2026). The company also revises a preliminary revenue estimate for the quarter ended March 31, 2026 to approximately $0.9 million to $1.0 million, down from an earlier estimate of $1.2 million; final results remain subject to quarter-end close.
PRSO is updating its shelf registration to allow additional at-the-market sales of common stock through Ladenburg Thalmann. The company may now offer and sell, from time to time, shares of common stock having an aggregate offering price of up to $3,150,000 under its existing Sales Agreement, in addition to approximately $4,095,176 of shares already sold under prior supplements.
These sales are made under Form S-3 General Instruction I.B.6, which limits primary offerings to no more than one-third of public float in any 12-month period while public float remains below $75,000,000. As of November 21, 2025, PRSO’s public float was about $21,229,538, based on 9,150,663 shares held by non-affiliates. The stock trades on Nasdaq Capital Market under the symbol PRSO, with a last reported price of $0.8839 per share on November 20, 2025.
PRSO is updating its at-the-market stock offering program, allowing it to sell additional common shares with an aggregate offering price of up to $1,750,000 through Ladenburg Thalmann under an existing sales agreement. This fits within Form S-3 rules that cap primary offerings at one-third of its public float.
The company also outlines an ongoing unsolicited approach from Mobix Labs, which has moved from an initial stock-based proposal to a revised all-cash indication of $1.30 per share. Mobix has discussed a potential hostile exchange offer but, as of October 9, 2025, has not commenced any tender or exchange offer. The board is conducting a strategic review with financial and legal advisors and states there is no assurance any transaction with Mobix or others will occur.